First Manhattan Ups Vivus Proxy Ante By Proposing Zook As CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Vivus’ largest shareholder, First Manhattan Co., said former AstraZeneca commercial head Tony Zook has agreed to serve as CEO of the obesity drug developer if shareholders vote for FMC’s board nominees July 15.
You may also be interested in...
AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later
AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.